AKESO

AKESO 09926.HK (AKESO) Stock Price

Closed
AKESO
$7.23
-$0.55(-7.04%)

Content updated: 2026-11-22 22:54:00

Yesterday's Close
$7.77
Today's Open
$7.49
Today's High
$7.53
Today's Low
$7.16
Volume
949.13M shares
52-Week Range
$7.16-$19.89

As of 2026-11-22 22:54:00, AKESO 09926.HK (AKESO) was quoted at $7.23, a change of -$0.55 (-7.04%) from the previous close. The day's range was $7.16–$7.53, and the 52-week range was $7.16–$19.89.

Why Is AKESO 09926.HK (AKESO) Stock Falling?

AI Stock Price Analysis

Content updated: 2026-11-22 10:54:25

On 20 November the stock gapped down 3.3% on 1.2 times recent volume. An early bounce faded and it closed near the day's low. Sellers stayed active on rebounds; buyers only probed lower levels. The reset after the U.S. filing setback is still unfolding. With the downtrend intact, bottom-fishing looks premature.

Past 1W-19.00%Period Low $7.16Period High $8.93
Past 1M-38.36%Period Low $7.16Period High $11.83
Past 3M-38.26%Period Low $7.16Period High $14.22
Past 1Y-48.07%Period Low $7.16Period High $19.89

About AKESO 09926.HK (AKESO)

Akeso, Inc. is a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative antibody drugs that are affordable for patients worldwide. Since its inception, the company has built a unique end-to-end comprehensive new drug research and development platform, establishing an innovative R&D system centered on Tetrabody bispecific antibody development technology, antibody-drug conjugate (ADC) technology, T-cell engager (TCE) technology, siRNA/mRNA technology, and cell therapy technology, as well as an internationally standardized GMP production system and a mature commercialization system, becoming a competitive biomedical innovation company globally. As of now, the company has a total of over 50 innovative projects in development, covering multiple fields including oncology, autoimmune diseases, metabolic diseases, neurodegenerative diseases, and others. Seven self-developed products have been approved for marketing, namely Cadonilimab (PD-1/CTLA-4, trade name: Kaitanni), Ivonescimab (PD-1/VEGF, trade name: Yidafang), Penpulimab (PD-1, trade name: Annike), Inusimab (PCSK9, trade name: Yixining*), Ebdarokimab (IL-12/IL-23, trade name: Aidaluo), as well as Putelimab (PD-1, trade name: Puyouheng) licensed to Lepu Biopharma Co., Ltd. (stock code: 2157.HK) and Tagolimab (PD-L1, trade name: Ketailai) licensed to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Three products covering four new drug applications/new indication applications are under review by the NMPA. The company's overseas partner SUMMIT has submitted the first indication application for Ivonescimab, which has been accepted by the U.S. Food and Drug Administration (FDA). The company has a total of 27 products in the approved/clinical research stage, with 12 products in Phase III clinical trials and 15 products in Phase I/II clinical trials. Among the pipeline products, 18 are first-in-class or potentially first-in-class bispecific/multispecific antibodies, ADCs, and other innovative mechanism drugs. The company's vision is to become a globally leading biopharmaceutical enterprise by focusing on the research and development of innovative drugs, establishing internationally standardized production systems, and building a diversified business landscape.
Ticker / Exchanges
AKESO / --
Industry / Sector
-- / --
CEO
夏瑜
Headquarters
--
Official Website
http://www.akesobio.com
Listing Date
--

AKESO 09926.HK (AKESO) Derivatives Trading

AKESOTrade
Stocks

Trade U.S., Hong Kong, Japanese, and South Korean stocks directly. Selected U.S., Hong Kong, and South Korean stocks support 24/7 trading. You hold actual shares. Corporate actions such as dividends and stock splits are handled according to market rules.

AKESOTrade
CFD

Trade stock price movements through CFDs without holding the underlying shares. CFDs support long and short positions and leveraged trading. Be aware of spreads, trading fees, overnight fees, and liquidation risk.

AKESOUSDTTrade
Perpetual Futures

Contracts based on stock prices, with no expiration date. They support 24/7 long, short, and leveraged trading without holding the underlying shares. Be aware of funding fees and liquidation risk.

AKESO 09926.HK (AKESO) Company Financials

Valuation and Shares

Market Cap
$6.80B
P/E Ratio (TTM)
-47.92
P/B Ratio
5.46
Shares Outstanding
941.14M shares
Float Shares
941.14M shares
Dividend Yield (TTM)
0.00%

Financials · Actuals

Actual Value2022-FY2023-FY2024-FY2025-FY
Revenue$106.86M$577.42M$270.95M$389.89M
Net Profit-$181.43M$247.78M-$63.92M-$145.53M
Operating Cash Flow-$158.24M$314.81M-$67.30M-$120.89M

AKESO FAQ

What is the current stock price of AKESO 09926.HK (AKESO)?

x
As of 2026-11-22 22:54 (UTC+8), the latest available quote for AKESO 09926.HK (AKESO) is $7.23 USD, with a change of -$0.55 USD (-7.04%) from the previous trading day's close. Current market status: Closed.

How has AKESO 09926.HK stock performed over the past month?

x

What is the market cap of AKESO 09926.HK?

x

What are AKESO 09926.HK's latest financial results?

x

What factors may affect the stock price of AKESO 09926.HK (AKESO)?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.